What Apogee Therapeutics, Inc. told the SEC could break it.

Apogee owns no manufacturing facilities and outsources all preclinical and clinical drug supply, development, manufacturing, storage, distribution and testing to third parties. It has a sole-source relationship for the preclinical and clinical supply of both the drug substance and drug product of APG990 (a combination partner for APG279), APG333 (a combination partner for APG273) and APG808, and is still finalizing commercial supply arrangements for zumilokibart. Any disruption — including adverse events affecting a sole supplier — would negatively impact clinical development while the company works to identify and qualify alternate sources, a process that for biologics can take years. This single-source CMO concentration is a core supply vulnerability for a clinical-stage antibody developer.

“We have a sole source relationship for our preclinical and clinical supply of APG990, APG333, and APG808 drug substance and drug product.”

Because Apogee imports materials and outsources manufacturing (including from regions subject to new U.S. tariffs since February 2025, such as China and South Korea), it is exposed to pharmaceutical-specific trade actions. In September 2025 the administration announced plans to impose 100% tariffs on imported branded or patented pharmaceuticals unless the importer is building U.S. manufacturing capacity, and it is not yet clear whether such tariffs would apply to active pharmaceutical ingredients and bulk drug products imported for clinical trials. If they do, the cost of materials for Apogee's clinical trials could rise materially for a company that generates no product revenue and funds operations from equity raises.

“In September 2025, President Trump announced plans to impose 100% tariffs on imported branded or patented pharmaceuticals, unless the importing company is building U.S. manufacturing capacity.”